Browse the evidence

Distributing protein evenly across multiple meals to exceed the leucine threshold in each meal results in greater muscle mass gains compared to uneven distribution where only one meal exceeds the threshold.

Spread your protein intake evenly across 3-4 meals throughout the day. This ensures that each meal triggers muscle protein synthesis. Avoid skipping meals or concentrating all your protein into one large meal, as this wastes potential anabolic opportunities and may lead to visceral fat deposition rather than muscle growth.

GLP-1 receptor agonists (semaglutide, tirzepatide) and Roux-en-Y gastric bypass (RYGB) surgery extend the duration of weight loss before reaching a plateau by weakening the physiological appetite feedback control circuit, whereas calorie restriction fails to weaken this circuit, leading to an earlier plateau.

If you are using GLP-1 medications or had bariatric surgery, your body's 'starvation signal' (appetite feedback) is chemically or surgically dampened, which is why you can lose weight for longer than diet-only approaches allow. Do not mistake the eventual plateau for failure; it is a sign that the feedback loop has stabilized. Calorie restriction alone fights this feedback loop directly, causing an earlier plateau.

Stronger individual identities as a 'healthy eater' or 'exerciser' are associated with positive changes in eating and physical activity behaviors, which mediate weight loss during major life events like the COVID-19 pandemic.

To maintain weight during stressful life events, focus on reinforcing your identity as a 'healthy eater' or 'exerciser' rather than relying solely on your environment. The study shows that identifying with these behaviors is a stronger predictor of success than neighborhood walkability or food availability.

Less discouragement from family and friends regarding healthy eating is associated with positive changes in eating behavior and subsequent weight loss.

If your social circle actively criticizes your healthy eating choices, this negative feedback is a significant barrier to weight loss. Mitigate this by minimizing exposure to such criticism or seeking support from those who do not discourage your dietary efforts.

Improving self-efficacy for controlling eating (resisting overeating in various situations) during the first month of a digital weight loss intervention is associated with increased dietary self-monitoring engagement, but not with significant weight loss at 3 months.

Building confidence in your ability to resist overeating in difficult situations (like parties or stress) can help you stick to your food tracking habits in a digital weight loss program. However, this specific confidence boost alone may not be enough to guarantee weight loss; you must also build confidence in the act of tracking your food itself.

GLP-1 agonist use (specifically semaglutide) is associated with a reduction in body mass index (from 34.1 ± 9 to 30.6 ± 6) and a decrease in smoking frequency/amount (by 14.4%) among users in Saudi Arabia.

If you are using GLP-1 agonists like semaglutide for weight loss, this study suggests you may also see a reduction in smoking frequency. However, be aware that cost and side effects are major reasons people stop taking the medication. To maintain weight loss, consistent use and healthy lifestyle habits (diet and exercise) are crucial, as obesity is a chronic condition requiring long-term management.

Early slow responders to bariatric surgery (low EWL at 3 months) should be identified through routine monitoring and offered intensified interventions, including pharmacologic support like GLP-1 receptor agonists.

If you are losing weight slower than expected in the first 3 months, talk to your doctor. You may be a 'slow responder,' and this is a known risk factor. Your team can offer extra support, such as dietary counseling, behavioral therapy, or medications like GLP-1 agonists, to help you get back on track.

Semaglutide treatment is associated with a 26% lower risk of fractures compared to sleeve gastrectomy in adults with obesity.

If you are at high risk for fractures (e.g., older age, diabetes, history of falls) and need to lose weight, discuss semaglutide with your provider. This study suggests it may be safer for your bones than sleeve gastrectomy, offering a 26% lower fracture risk in a large real-world cohort. However, because this is observational data, ensure you monitor your bone health and nutrition regardless of the chosen path.

Enobosarm (3-6 mg/day) preserves total lean mass and reduces fat mass loss when co-administered with semaglutide for weight loss in older adults with overweight/obesity, without compromising overall body weight reduction.

If you are taking semaglutide for weight loss and are concerned about losing muscle, ask your doctor about adding enobosarm (3-6 mg daily). Recent Phase 2b data suggests this combination preserves lean mass and increases fat loss compared to semaglutide alone, without changing total weight loss. Note that this specific combination is still under regulatory review and not yet approved.

GLP-1 receptor agonists (Liraglutide and Semaglutide) promote weight loss and modulate gut microbiota towards a lean-related profile, although clinical data on their specific impact on gut microbiota composition is currently limited.

GLP-1 agonists like Liraglutide and Semaglutide are effective pharmacological treatments for obesity, producing significant weight loss (approx. 6-8%) when combined with lifestyle changes. While they show promise in improving gut microbiota in animal studies, clinical data on these specific changes is still emerging.

GLP-1 receptor agonists (GLP1-RAs) and dual GIP/GLP1-RAs (e.g., tirzepatide) significantly reduce body fat distribution (visceral, subcutaneous, epicardial) and anthropometric indices (BMI, waist circumference) in overweight or obese adults with or without type 2 diabetes.

If you are overweight or obese, especially with type 2 diabetes, GLP-1 receptor agonists are a proven pharmacological option to reduce body fat, including dangerous visceral fat, and improve metabolic health. These medications work by targeting hormones that regulate appetite and satiety. Consult a doctor to see if an injectable medication like semaglutide or tirzepatide is appropriate for your specific health profile and goals.

In patients with BMI ≥35 kg/m², improvements in glomerular filtration rate (GFR) are driven by the magnitude of weight loss and baseline renal function, regardless of whether the weight loss is achieved via metabolic and bariatric surgery (MBS) or high-dose GLP-1 agonist therapy.

For obese patients (BMI ≥35) concerned about kidney health, achieving significant weight loss is the key factor for improving glomerular filtration rate (GFR). Both high-dose GLP-1 agonists (like 3mg liraglutide) and bariatric surgery can improve kidney function to a similar degree, provided they result in substantial weight loss. The choice between medication and surgery should be based on patient preference and tolerability, as renal outcomes appear equivalent when weight loss is achieved.

In patients with overweight/obesity and established atherosclerotic cardiovascular disease (ASCVD), treatment with semaglutide 2.4 mg significantly reduces total annual medical costs and inpatient healthcare resource utilization compared to non-treated controls.

For patients with obesity and heart disease, using semaglutide 2.4 mg is associated with lower total medical bills over a year, primarily because it reduces the need for hospital stays. This suggests the drug can be cost-effective for this specific population by preventing expensive cardiovascular events.

GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) induce significant weight loss and modify inflammatory markers, suggesting potential oncological benefit, but high-quality data on cancer incidence is currently lacking.

GLP-1 agonists are effective for weight loss and may reduce cancer risk, but long-term cancer data is not yet available. They are a viable option for those who cannot undergo surgery.

GLP-1 receptor agonists (GLP-1RAs) are perceived by patients as effective for weight loss and appetite reduction, with positive treatment experiences correlating with therapy duration of 6 months or longer.

If you are considering GLP-1 medication, know that most patients report significant benefits for weight and appetite, especially if they stay on it for at least 6 months. Be prepared to discuss insurance coverage and side effects openly with your doctor to overcome common barriers.

Antiobesity medications (AOMs), including both injectable GLP-1 receptor agonists and oral formulations, produce similar weight loss outcomes and safety profiles in patients with celiac disease on a gluten-free diet as they do in patients without celiac disease.

If you have celiac disease and are on a gluten-free diet, antiobesity medications (like semaglutide or liraglutide) are likely to work for you just as well as they do for people without celiac disease. You do not need to avoid these medications due to fears about gut absorption, provided your celiac disease is managed with a strict gluten-free diet.

Silibinin (150-300 mg) and thistle extract inhibit human pancreatic lipase in vivo, leading to increased fecal fat excretion and reduced waist circumference, with a significantly lower adverse effect profile compared to orlistat.

Taking 150-300 mg of silibinin or thistle extract with meals may help reduce abdominal fat by blocking some dietary fat absorption, with fewer gastrointestinal side effects than prescription fat-blockers like orlistat. However, this was observed in a very short-term study of healthy, normal-weight people, so long-term efficacy and safety for weight loss in obese individuals remain unproven.

Integrative Korean Medicine Treatment (IKMT), comprising personalized herbal medicine (including Ephedrae Herba) and dietitian-led lifestyle modification, produces statistically significant weight loss and blood pressure reductions in obese adults with a safety profile comparable to or better than GLP-1 receptor agonists.

This study suggests that a structured program combining personalized herbal medicine (specifically containing Ephedrae Herba) with professional dietary coaching can lead to significant weight loss (average ~8.7%, up to ~28% in best responders) and improved blood pressure. It serves as a viable alternative for individuals who cannot tolerate or afford GLP-1 medications, provided they undergo proper medical screening for contraindications like heart or liver disease.

GLP-1 receptor agonists (exenatide, liraglutide) are effective for weight loss in patients with schizophrenia who are gaining weight due to antipsychotic medications (clozapine/olanzapine).

For patients with schizophrenia taking clozapine or olanzapine who experience significant weight gain, GLP-1 agonists (exenatide or liraglutide) are a promising treatment option. They effectively reduce weight gain (avg 3.71 kg difference) without interacting with the antipsychotic medications, avoiding the need to change psychiatric treatment.

GLP-1 receptor agonists (Liraglutide, Semaglutide) are effective and safe for treating obesity in children and adolescents, with FDA approval for Liraglutide in this population.

For children and adolescents with obesity, Liraglutide is an FDA-approved option. It helps reduce weight (avg 2.74 kg in trials) and improves HbA1c. Side effects are generally mild GI symptoms or minor hypoglycemia. It should be used alongside diet and exercise.

Virtual delivery of a full meal replacement (FMR) intensive lifestyle intervention program yields weight loss outcomes statistically equivalent to in-person delivery.

If you are considering a meal replacement weight loss program, delivering it virtually (via video) is just as effective as doing it in person. In fact, virtual participants attended more sessions, which may contribute to the comparable weight loss results. You do not need to travel to a clinic to achieve significant weight loss with this protocol.

Pre-existing use of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) is significantly associated with reduced weight loss in patients undergoing a Full Meal Replacement (FMR) intensive lifestyle intervention.

If you are currently taking a GLP-1 RA (like Ozempic or Wegovy) and start a strict meal replacement program, you might not lose as much weight as expected compared to those not on the medication. This does not mean the medication is ineffective, but its interaction with the FMR protocol may differ from standard expectations. Discuss this with your provider.

GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) reduce cancer risk in overweight/obese individuals primarily through sustained weight loss and secondarily through weight-loss-independent anti-inflammatory and metabolic mechanisms.

For individuals with obesity, GLP-1/GIP agonists (like semaglutide or tirzepatide) are more effective than diet alone for achieving sustained weight loss, which is linked to reduced cancer risk. These medications work by reducing hunger and improving metabolic health. While they require ongoing use and can be costly, they offer a clinically significant advantage over lifestyle changes alone for those who struggle with long-term adherence.

GLP-1 receptor agonists used for weight management are associated with nutritional deficiencies, specifically protein deficiency and metabolic acidosis, which may lead to malnutrition.

When using GLP-1 medications for weight loss, pay attention to your nutrition. Reports suggest a higher risk of protein deficiency and metabolic acidosis. Ensure you are eating enough protein and staying hydrated. If you feel unwell, dizzy, or experience unusual symptoms, talk to your doctor about your diet and medication.